Trinity Biotech gains European approval for the Meritas® Troponin I (TnI) point-of-care test

Trinity Biotech is pleased to announce that its landmark, high sensitivity Meritas® Troponin I (TnI) point-of-care (POC) test has obtained CE marking, making it the only POC product capable of meeting all the guidelines stipulated by the world’s leading cardiac organizations for the detection of heart attacks. With CE marking achieved, the Company now intends to release the product for sale in Europe and other carefully selected markets through its specialist Cardiology Distributor network and direct selling teams.

Designed for use with the revolutionary, state-of-the-art Meritas POC Analyzer, the Meritas Troponin I test enables fast, accurate triage and intervention for patients presenting at the emergency department with a possible myocardial infarction (MI. Results, which are traceable to NIST SRM 2921, are comparable to those obtained using traditional top performing laboratory analyzers, and are available in just 15 minutes. Turnaround times, patient care and outcomes are improved, helping to maximize the use of precious hospital resources and generate significant cost savings. Additional assays are currently being developed to extend the test menu further.